傲农生物发预减，预计2025年年度归母净利润同比减少76.70%到84.47%

Core Viewpoint - Aonong Biological (603363.SH) forecasts a significant decline in net profit for the year 2025, estimating a range of 90 million to 135 million yuan, which represents a decrease of 444.35 million to 489.35 million yuan compared to the previous year, equating to a year-on-year decline of 76.70% to 84.47% [1] Summary by Categories Financial Performance - The company expects a net profit attributable to shareholders of 90 million to 135 million yuan for 2025, a substantial decrease from the previous year [1] - The anticipated decline in profit is attributed to a reduction in debt scale and interest expenses due to bankruptcy restructuring, alongside significant losses from asset impairment and bad debt provisions totaling approximately 200 million yuan [1] Operational Developments - Following bankruptcy restructuring, the company has seen a significant reduction in debt and interest expenses, with some idle assets divested and core pig farming operations gradually resuming [1] - The company reports a rapid recovery in sow inventory and improved production performance across its main business segments, including pig farming, feed, and slaughtering [1] Asset Management - The first year post-restructuring has resulted in some assets still not being operational, leading to depreciation and amortization costs of about 80 million yuan for the year [1] - The benefits from debt restructuring are expected to decline significantly compared to 2024, impacting overall financial performance [1]